Related Experiment Videos
[Treatment with angiotension converting enzyme inhibitors]
F Delahaye1, G de Gevigney, L Meunier
1Hôpital cardiovasculaire et pneumologique, Lyon.
Archives Des Maladies Du Coeur Et Des Vaisseaux
|September 28, 1998
Summary
Angiotensin converting enzyme (ACE) inhibitors significantly reduce mortality in high-risk myocardial infarction patients. Treatment duration and patient selection are key considerations for optimal outcomes in post-myocardial infarction care.
Area of Science:
- Cardiology
- Pharmacology
Context:
- Eight randomized clinical trials involving over 100,000 patients evaluated ACE inhibitors post-myocardial infarction.
- High-risk myocardial infarction patients face a poor prognosis with high mortality rates.
Purpose:
- To assess the efficacy of angiotensin converting enzyme (ACE) inhibitors in reducing mortality following myocardial infarction.
- To determine optimal treatment strategies, including patient selection, timing, duration, and drug choice.
Summary:
- ACE inhibitors demonstrated significant benefits in high-risk myocardial infarction patients, with relative risk reductions of 19-27% and absolute risk reductions of 4-8% in mortality.
- In broader myocardial infarction populations, the mortality benefits were less pronounced, with smaller relative and absolute risk reductions.
- Optimal treatment involves selecting appropriate patients, initiating therapy early (day 1 or 2), and continuing long-term, especially for high-risk individuals.
Impact:
- ACE inhibitors are crucial in managing myocardial infarction, particularly in high-risk groups, leading to improved survival rates.
- The findings guide clinical practice regarding the use of ACE inhibitors, influencing treatment protocols and patient management strategies.
- Further research may refine optimal dosing and specific ACE inhibitor selection for diverse patient populations.